Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Bank of America Corp DE

Bank of America Corp DE decreased its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 71.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 184,464 shares of the company's stock after selling 451,268 shares during the period. Bank of America Corp DE owned 0.31% of Twist Bioscience worth $8,572,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TWST. Benjamin Edwards Inc. lifted its holdings in shares of Twist Bioscience by 39.7% in the 4th quarter. Benjamin Edwards Inc. now owns 17,706 shares of the company's stock worth $823,000 after buying an additional 5,033 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Twist Bioscience by 138.0% in the fourth quarter. BNP Paribas Financial Markets now owns 90,527 shares of the company's stock valued at $4,207,000 after acquiring an additional 52,495 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in Twist Bioscience in the fourth quarter worth about $2,677,000. First Light Asset Management LLC bought a new position in Twist Bioscience during the 4th quarter worth about $56,984,000. Finally, Northern Trust Corp grew its holdings in Twist Bioscience by 9.0% during the 4th quarter. Northern Trust Corp now owns 627,649 shares of the company's stock worth $29,167,000 after acquiring an additional 51,926 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, COO Patrick John Finn sold 1,877 shares of the firm's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer now owns 240,783 shares in the company, valued at approximately $7,163,294.25. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 2,402 shares of Twist Bioscience stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the transaction, the chief executive officer now directly owns 662,692 shares of the company's stock, valued at $27,110,729.72. The trade was a 0.36% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,011 shares of company stock valued at $951,499. 3.01% of the stock is owned by company insiders.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $1.15 during midday trading on Tuesday, reaching $29.41. The company's stock had a trading volume of 1,289,530 shares, compared to its average volume of 978,712. The firm has a market capitalization of $1.76 billion, a PE ratio of -8.70 and a beta of 2.54. The stock has a fifty day moving average of $36.44 and a 200 day moving average of $42.69. Twist Bioscience Co. has a twelve month low of $27.12 and a twelve month high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. On average, equities analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Robert W. Baird dropped their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Barclays dropped their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. The Goldman Sachs Group lowered their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. cut their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.